KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Tax Provisions (2016 - 2025)

West Pharmaceutical Services' Tax Provisions history spans 17 years, with the latest figure at $33.3 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 9.51% year-over-year to $33.3 million; the TTM value through Dec 2025 reached $121.6 million, up 13.12%, while the annual FY2025 figure was $121.6 million, 13.12% up from the prior year.
  • Tax Provisions for Q4 2025 was $33.3 million at West Pharmaceutical Services, down from $34.0 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $44.2 million in Q2 2022 and bottomed at $12.0 million in Q3 2021.
  • The 5-year median for Tax Provisions is $29.8 million (2023), against an average of $28.7 million.
  • The largest YoY upside for Tax Provisions was 101.87% in 2021 against a maximum downside of 43.13% in 2021.
  • A 5-year view of Tax Provisions shows it stood at $34.2 million in 2021, then decreased by 15.5% to $28.9 million in 2022, then rose by 19.38% to $34.5 million in 2023, then grew by 6.67% to $36.8 million in 2024, then decreased by 9.51% to $33.3 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Tax Provisions are $33.3 million (Q4 2025), $34.0 million (Q3 2025), and $30.2 million (Q2 2025).